KRAS and Miyoshi myopathy: The prevalence of KRAS, NRAS and BRAF mutations in our patient cohort (38%, 23% and 11%, respectively) was higher compared to previously published data (23–26%, 20–24% and 4–6% of MM cases, respectively) obtained from shallow genome (30 × ) and whole exome (100 × ) sequencing studies in MM patients3, 4.